Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 11;11:9983. doi: 10.1038/s41598-021-89016-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Association between mutational and neoepitope landscapes. BLCA mutanomes were analyzed with Ancer to determine counts of Ancer-defined HLA class I neoepitopes (a), Ancer-defined HLA class II neoepitopes (b), and Ancer-defined neoantigen candidates that could be used for precision immunotherapy purposes (c). Numbers of HLA class I neoepitopes, HLA class II neoepitopes, and neoantigen candidates observed in each patient is strongly correlated with observed tumor mutational burden (TMB). Each dot corresponds to one TGCA BLCA patient.